Heron Therapeuti Ownership
| HRTX Stock | USD 2.39 0.07 3.02% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 152 M | Current Value 153 M | Avarage Shares Outstanding 55.6 M | Quarterly Volatility 46 M |
Heron |
Heron Stock Ownership Analysis
About 77.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.09. Heron Therapeuti had not issued any dividends in recent years. The entity had 1:20 split on the 13th of January 2014. Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people. To learn more about Heron Therapeuti call Barry PharmD at (858) 251-4400 or check out https://www.herontx.com.Besides selling stocks to institutional investors, Heron Therapeuti also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Heron Therapeuti's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Heron Therapeuti's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Heron Therapeuti Quarterly Liabilities And Stockholders Equity |
|
Heron Therapeuti Insider Trades History
Less than 1% of Heron Therapeuti are currently held by insiders. Unlike Heron Therapeuti's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Heron Therapeuti's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Heron Therapeuti's insider trades
Heron Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Heron Therapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Heron Therapeuti backward and forwards among themselves. Heron Therapeuti's institutional investor refers to the entity that pools money to purchase Heron Therapeuti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.8 M | Congress Park Capital Llc | 2024-12-31 | 2.5 M | Jw Asset Management, Llc | 2024-12-31 | 2.3 M | Tang Capital Management Llc | 2024-12-31 | 2.1 M | Orchard Capital Management, Llc | 2024-12-31 | 1.9 M | Clearline Capital Lp | 2024-12-31 | 1.8 M | New York State Common Retirement Fund | 2024-12-31 | 1.3 M | Monaco Asset Management | 2024-12-31 | 1.2 M | Renaissance Technologies Corp | 2024-12-31 | 1.2 M | Rubric Capital Management Lp | 2024-12-31 | 26.7 M | Blackrock Inc | 2024-12-31 | 8.6 M |
Heron Therapeuti Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Heron Therapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Heron Therapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Heron Therapeuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Heron Therapeuti Outstanding Bonds
Heron Therapeuti issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Heron Therapeuti uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Heron bonds can be classified according to their maturity, which is the date when Heron Therapeuti has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Heron Therapeuti Corporate Filings
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 5th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 24th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.